Lenalidomide

EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings

Retrieved on: 
Giovedì, Maggio 11, 2023
Ruxolitinib, Partnership, Peripheral T-cell lymphoma, MorphoSys, European Hematology Association, Primary myelofibrosis, Half-life, American Society of Clinical Oncology, Bone marrow, Lenalidomide, Joint Planning and Development Office, FSE, Immunotherapy, ASCO, BET, Pancreatic serous cystadenoma, Intolerance, Cancer, Patient, Lymphoma, EHA, Annual general meeting, EZH2, EZH1, Society, Disease, Pharmaceutical industry, Medical imaging, Tafasitamab, Hydroxycarbamide

“The data we are presenting at ASCO and EHA showcase the breadth and depth of our mid- to late-stage pipeline.

Key Points: 
  • “The data we are presenting at ASCO and EHA showcase the breadth and depth of our mid- to late-stage pipeline.
  • Monjuvi in combination with lenalidomide was investigated in the Phase 2 L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.
  • The presentations on Monjuvi include:
    An e-publication at ASCO and EHA of a new five-year sub-group analysis from L-MIND.
  • At ASCO, preliminary results from the Phase 2 portion of the study evaluating tulmimetostat across multiple tumor types will be presented during a poster session.

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Giovedì, Maggio 11, 2023
Topotecan, GLP, Carcinoma, Abstract, Rituximab, LSD1, AACR, Cancer prevention, Follicular lymphoma, DLBCL, European Hematology Association, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Biotechnology, Clinical trial, Lenalidomide, NHL, CD20, American Association for Cancer Research, Cyclophosphamide, Salinicola salarius, SCLC, Bortezomib, Congress, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Patient, Toxicology, Neoplasm, Ewing sarcoma, Research institute, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, News, Food, Cancer Prevention and Research Institute of Texas, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Video game

HOUSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $9.3 million as of March 31, 2023, compared with $12.1 million as of December 31, 2022.
  • The decline reflects lower spending on seclidemstat in the 2023 quarter and one-time expenses of $2.0 million related to the purchase of the targeted protein degrader program in the 2022 quarter.
  • “In addition, Salarius continued to execute on plan during the first quarter of 2023 and recent weeks as we advanced the development of SP-3164, our targeted protein degrader.
  • Salarius will be participating in the 2023 BIO International Convention in Boston June 5-8, and the European Hematology Association 2023 Congress in Frankfurt, Germany June 8-11.

EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results

Retrieved on: 
Mercoledì, Maggio 3, 2023
Workforce, Rituximab, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Ruxolitinib, Vincristine, AACR, MorphoSys, Doctor of Philosophy, Significant event audit, JAK, DLBCL, Conference call, Lenalidomide, American Association for Cancer Research, Cyclophosphamide, FSE, Incyte, Sale, ASCO, BET, Prednisone, American Society of Clinical Oncology, Patient, Doxorubicin, Annual general meeting, Webcast, Society, Conference, Safety, Security (finance), Nursing, Beauty salon, Video game, Pharmaceutical industry, Tafasitamab

Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023

Key Points: 
  • Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023
    € 791.5 million in cash and other financial assets as of March 31, 2023
    Conference call and webcast (in English) tomorrow, May 04, 2023, at 2:00pm CEST (1:00pm BST/8:00am EDT)
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the first quarter 2023 (Q1 2022: € 0.7 million).
  • On March 14, 2023, MorphoSys announced that Lucinda Crabtree, Ph.D., will join the company as its Chief Financial Officer and member of the Management Board in the third quarter of 2023 at the latest.
  • Total revenues for the first quarter 2023 were € 62.3 million compared to € 41.5 million for the same period in 2022.

MorphoSys AG Reports First Quarter 2023 Financial Results

Retrieved on: 
Mercoledì, Maggio 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Workforce, Rituximab, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Ruxolitinib, Vincristine, AACR, MorphoSys, Doctor of Philosophy, Significant event audit, JAK, DLBCL, Lenalidomide, American Association for Cancer Research, Cyclophosphamide, FSE, Incyte, Sale, ASCO, BET, Prednisone, American Society of Clinical Oncology, Patient, Doxorubicin, Annual general meeting, Society, Safety, Beauty salon, Nursing, Video game, Pharmaceutical industry, Tafasitamab

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the first quarter 2023 (Q1 2022: € 0.7 million).
  • On March 14, 2023, MorphoSys announced that Lucinda Crabtree, Ph.D., will join the company as its Chief Financial Officer and member of the Management Board in the third quarter of 2023 at the latest.
  • Total revenues for the first quarter 2023 were € 62.3 million compared to € 41.5 million for the same period in 2022.

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Giovedì, Aprile 20, 2023
Immortalised cell line, Abstract, AACR, Follicular lymphoma, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Lenalidomide, NHL, American Association for Cancer Research, Bortezomib, Patient, Apoptosis, Poster, Pharmaceutical industry, Vaccine, Salinicola salarius

HOUSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced the presentation of two posters related to the company’s novel molecular glue, SP-3164, at the American Association for Cancer Research (AACR) Annual Meeting. Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).

Key Points: 
  • Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).
  • “These two studies presented at the prestigious AACR Annual Meeting are adding to the growing body of SP-3164 preclinical data demonstrating anticancer activity alone and in combination with standard-of-care treatments,” said David Arthur, president and chief executive officer of Salarius.
  • In addition, the data showed SP-3164 induced apoptosis in multiple myeloma cell lines.
  • In animal models, SP-3164 demonstrated superior single-agent activity compared to both lenalidomide (Revlimid®) and pomalidomide (Pomalyst®).

Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting

Retrieved on: 
Martedì, Aprile 18, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DUSP6, Abstract, AACR, Tyrosine, Therapy, MCD, ADCC, Tafasitamab, DLBCL, Multiple myeloma, Neoplasm, Immunomodulatory imide drug, Lenalidomide, Anti-CD19 immunotoxin, NHL, BRAF, MEK, IC50, BTK, SHP2, Messenger, SSE, HKEX, RAS, Patient, EGFR, RTK, NF1, III, Safety, Vaccine, Extrusion, Pharmaceutical industry

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • In various multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) tumor models, ICP-490 demonstrates superior tumor killing activities, including overcoming lenalidomide resistance.
  • Cell viability assays reveal robust in vitro efficacies of ICP-490 against various MM and NHL(including DLBCL) cell lines with nanomolar IC50.
  • In contrast to its tumor killing effect, ICP-490 shows no cytotoxicity against normal human cells.

EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Retrieved on: 
Lunedì, Aprile 17, 2023
AACR, MorphoSys, Diarrhea, Progression-free survival, NR, DLBCL, Plot, Aes, Lenalidomide, Joint Planning and Development Office, American Association for Cancer Research, FSE, Refractory, Immunotherapy, Teaching hospital, Incidence, Durability, ASCT, Patient, CR, Oncology, FDA, Abstract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Thrombocytopenia, Polyclinic, ORR, Food, PR, Disease, Pharmaceutical industry, Nursing, Relapse, Tafasitamab, Neutropenia

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Key Points: 
  • MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
    BOSTON and WILMINGTON, Del.
  • Monjuvi, in combination with lenalidomide, was granted accelerated approval based on the one-year primary analysis of the L-MIND study.
  • The data for the five-year analysis of the L-MIND study have not yet been submitted to, or reviewed by, the FDA.

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Retrieved on: 
Domenica, Aprile 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, AACR, MorphoSys, Diarrhea, Progression-free survival, NR, DLBCL, Plot, Aes, Lenalidomide, Joint Planning and Development Office, American Association for Cancer Research, FSE, Multimedia, Immunotherapy, Teaching hospital, Incidence, ASCT, Patient, CR, Oncology, Abstract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Thrombocytopenia, Polyclinic, ORR, Food, PR, Disease, Pharmaceutical industry, Nursing, Tafasitamab, Neutropenia

A partial response (PR) was observed in 16.2% of patients (95% CI = 8.9, 26.2; n =13).

Key Points: 
  • A partial response (PR) was observed in 16.2% of patients (95% CI = 8.9, 26.2; n =13).
  • Additional results include:
    Median duration of response was not reached after a median follow up of 44.0 months (95% CI = 29.9, 57.0).
  • Monjuvi, in combination with lenalidomide, was granted accelerated approval based on the one-year primary analysis of the L-MIND study.
  • The data for the five-year analysis of the L-MIND study have not yet been submitted to, or reviewed by, the FDA.

EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

Retrieved on: 
Sabato, Aprile 15, 2023
Rituximab, Ruxolitinib, Vincristine, MorphoSys, Primary myelofibrosis, Tafasitamab, JAK, Hematology, Fever, Weight loss, Lenalidomide, Bone marrow, Joint Planning and Development Office, Quality of life, Cyclophosphamide, FSE, B-cell lymphoma, Pain, BET, Prednisone, Spleen, Patient, Standard of care, Doxorubicin, Pancreatic serous cystadenoma, Society, Safety, Fatigue, Disease, Pharmaceutical industry, Medical imaging

The topline data are now expected by the end of 2023, earlier than previously anticipated.

Key Points: 
  • The topline data are now expected by the end of 2023, earlier than previously anticipated.
  • Myelofibrosis – which belongs to a group of diseases called myeloproliferative disorders – is a difficult-to-treat form of blood cancer with limited treatment options.
  • Enrollment of the Phase 3 frontMIND study is also complete, with more than 880 patients enrolled in the trial.
  • The topline data from this study are expected in the second half of 2025.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Lunedì, Marzo 27, 2023
Myelodysplastic syndrome, Abstract, Rituximab, AACR, University, Cell death, ASH, Cancer prevention, Sarcoma, Multiple myeloma, Drug discovery, Clinical trial, Bone marrow, Lenalidomide, NHL, Chronic myelomonocytic leukemia, American Association for Cancer Research, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Research, MD Anderson Cancer Center, Monroe Dunaway Anderson, Salinicola salarius, Azacitidine, Protein, Acquisition, Patent, Patient, Mouse, Research institute, Ewing sarcoma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, Factorization of polynomials, Food, Cancer Prevention and Research Institute of Texas, Cryptocurrency, Video game, Pharmaceutical industry, Rail freight transport, Vaccine

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021.
  • Research and development expenses were $4.7 million in the fourth quarter of 2022, compared with $2.7 million in the fourth quarter of 2021.
  • As of December 31, 2022, Salarius had cash, cash equivalents and restricted cash of $12.1 million, compared with $29.2 million as of December 31, 2021.
  • Current cash and cash equivalents are expected to fund the company’s planned operations into the fourth quarter of 2023.